相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia
Oliver G. Ottmann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Andrew H. Wei et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
Courtney L. DiNardo et al.
LANCET ONCOLOGY (2018)
Interpretation of clinical endpoints in trials of acute myeloid leukemia
Bruno C. Medeiros
LEUKEMIA RESEARCH (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Response Rates as Predictors of Overall Survival: A Meta-Analysis of Acute Myeloid Leukemia Trials
Suresh K. Agarwal et al.
JOURNAL OF CANCER (2017)
Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors
Hiroshi Nokihara et al.
INVESTIGATIONAL NEW DRUGS (2016)
Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients
Nienke A. de Glas et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
New drug approvals in acute myeloid leukemia: what's the best end point?
E. Estey et al.
LEUKEMIA (2016)
Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients
Nienke A. de Glas et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis
Shiv Kumar et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
B. T. Gjertsen et al.
LEUKEMIA (2015)
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
Hartmut Doehner et al.
BLOOD (2014)
An Open-Label, Single-Arm, Phase 2 Trial of the PoloLike Kinase Inhibitor Volasertib ( BI 6727) in Patients With Locally Advanced or Metastatic Urothelial Cancer
Walter M. Stadler et al.
CANCER (2014)
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival
Alan K. Burnett et al.
BLOOD (2013)
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison
A. K. Burnett et al.
LEUKEMIA (2013)
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2012)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
Gunnar Juliusson et al.
BLOOD (2009)
Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells
Annelies G. Renner et al.
BLOOD (2009)
BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
Dorothea Rudolph et al.
CLINICAL CANCER RESEARCH (2009)
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
Alan K. Burnett et al.
CANCER (2007)
分享论文
